Statistical Report: Out of 90 serious Covid-19 patients treated with the new drug, 93 percent were released in five days or less

In a Phase II trial for an Israeli COVID drug, 29 out of 30 moderate to severe patients recovered within days.

In a Phase II trial of the medication, 93 percent of 90 coronavirus severe patients treated in multiple Greek hospitals with a new drug created by a team at Tel Aviv's Sourasky Medical Center were released in five days or less.

The results of the Phase I experiment, which was done in Israel last winter and saw 29 out of 30 patients in moderate to serious condition recover within days, were confirmed in the Phase II trial.

Prof. Nadir Arber stated, "The main purpose of this study was to prove that the medicine is safe." “To yet, no serious side effect has been observed in any patient from either group.” Because Israel lacked enough relevant patients, the experiment was held in Athens. Prof. Sotiris Tsiodras, Greece's coronavirus commissioner, was the lead investigator.

The medicine was developed by Arber and his team, which included Dr. Shiran Shapira, based on a molecule called CD24 that the professor has been studying for 25 years and is naturally present in the body.

“It's vital to keep in mind that 19 out of every 20 COVID-19 individuals do not require treatment,” Arber added. “After a five-to-twelve-day interval, about 5% of the patients begin to deteriorate.”

An overactive immune system, often known as a cytokine storm, is the primary cause of clinical deterioration. In COVID-19 individuals, the immune system begins to assault healthy cells in the lungs.“This is precisely the issue that our drug addresses,” he explained.

CD24 is a tiny protein that is linked to the cell membrane and has a variety of activities, including regulating the cytokine storm process.Arber emphasized that their medication, EXO-CD24, does not influence the immune system as a whole, but rather focuses on one specific mechanism, assisting in its restoration.He explained, "This is precision medicine." “We are overjoyed that we have discovered a way to combat the disease's physiology.”

The team is now ready to begin the study's final phase.“As encouraging as the early findings of a treatment may be, no one can be certain of anything until the results are compared to those of patients who receive a placebo,” he said. Arber stated, "We plan to finish it by the end of the year." If the findings are confirmed, he promises that the treatment will be available soon and at a low cost.“Moreover, success could pave the way for many more ailments to be treated,” he added.

This is credit to ROSSELLA TERCATIN as the author of this work.

Reference

https://www.jpost.com/health-science/covid-90-percent-of-patients-treated-with-new-israeli-drug-discharged-in-5-days-675961?fbclid=IwAR2hzKwm3Kh7Gv5uRYOss4NgUFb4k89sz84s2bV2YJnpHItzyUFfTi_Spx8

You can also visit relevant to COVID-19

Research shows about Ivermectin to COVID-19